Kevzara Injection, Solution
Product Images NDC 0024-5920

Product Visual Gallery

This gallery contains 53 technical images submitted to the FDA as part of the official labeling for Kevzara (NDC 0024-5920). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sanofi-aventis U.s. Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Kevzara 01)

A line graph depicting the percentage of patients with ACR20 response over 24 study weeks. It compares three groups receiving Placebo + MTX, KEVZARA 150 mg + MTX, and KEVZARA 200 mg + MTX. The x-axis shows study weeks from 0 to 24, and the y-axis shows the percent of patients with ACR20 response, ranging from 0% to 100%. The graph displays increasing response rates over time for KEVZARA groups compared to placebo.*

FDA Label Image

Image (Kevzara 01a)

An instructional diagram of the KEVZARA (sarilumab) injection, showing the parts of a prefilled syringe for subcutaneous use. Labeled components include the plunger, finger grip, label, expiry date, syringe body, needle cap, and needle. A magnified inset highlights the needle and needle cap.*

FDA Label Image

Image (Kevzara 01b)

An instructional illustration showing a hand using a pen-type injector device positioned over a syringe inside an open box. The image likely demonstrates preparing or administering a subcutaneous injection, consistent with the KEVZARA injection, solution dosage form.*

FDA Label Image

Image (Kevzara 01c)

Packaging label for KEVZARA injection solution, strength 150 mg/1.14 mL, subcutaneous route. The label displays the proprietary name KEVZARA with the generic name sarilumab below it, along with the dosage strength. Also included is a section showing barcode areas for lot number and expiration date. The product is labeled by Sanofi-Aventis U.S. LLC.*

FDA Label Image

Image (Kevzara 01d)

An instructional diagram showing the cross-sectional view of a container or vial with a plunger and a liquid solution inside. The illustration highlights the interior and the plunger position, likely representing the mechanism of a prefilled syringe or injection device.*

FDA Label Image

Image (Kevzara 01e)

Illustration showing a KEVZARA 150 mg/1.14 mL injection, solution for subcutaneous use in a syringe with a yellow safety guard. A clock icon indicates a 30-minute time period, likely relating to administration or observation timing.*

FDA Label Image

Image (Kevzara 01f)

An anatomical illustration highlighting recommended subcutaneous injection sites for KEVZARA (sarilumab) injection, solution. The marked areas include the outer upper arms, abdomen excluding a 2-inch area around the navel, and the front of the thighs. These are shown as orange-shaded regions on a simplified human figure.*

FDA Label Image

Image (Kevzara 01g)

An instructional illustration showing a hand holding a prefilled syringe labeled KEVZARA (sarilumab) injection solution for subcutaneous use. The image depicts the removal of a cap from the syringe needle, indicated by an arrow pointing away from the cap.*

FDA Label Image

Image (Kevzara 01h)

An instructional illustration showing a hand pinching skin, likely demonstrating the technique for preparing an injection site for a subcutaneous injection.*

FDA Label Image

Image (Kevzara 01i)

An instructional illustration showing a hand holding a prefilled syringe angled at 45 degrees for subcutaneous injection, while the other hand pinches the skin to prepare for the injection. The image depicts the proper technique for administering a subcutaneous injection.*

FDA Label Image

Image (Kevzara 01j)

An instructional illustration showing a hand holding a Kevzara (sarilumab) prefilled syringe for subcutaneous injection. The syringe is angled with the needle cover being removed, demonstrating how to prepare the injection.*

FDA Label Image

Image (Kevzara 01k)

An instructional illustration showing a hand holding a syringe labeled 'KEVZARA injection,' preparing to administer a subcutaneous injection into the skin. The image highlights the proper angle and hand positioning for the injection procedure.*

FDA Label Image

Image (Kevzara 01m)

An instructional illustration depicting a hand holding a KEVZARA (sarilumab) prefilled syringe. The illustration shows the removal of the needle cap with downward arrows indicating the cap being discarded into a sharps container or disposal receptacle below.*

FDA Label Image

Image (Kevzara 01n)

An instructional illustration of a KEVZARA (sarilumab) prefilled syringe for subcutaneous injection. The diagram labels the syringe components, including the plunger, finger grip, product label with expiry date, syringe body, needle cap, and needle. A close-up inset highlights the needle and needle cap detail.*

FDA Label Image

Image (Kevzara 01o)

An instructional illustration showing a hand holding an orange safety cap over a prefilled syringe inside an open storage box. The box contains multiple syringes with orange caps arranged in compartments, demonstrating safe handling and storage of injectable medication syringes.*

FDA Label Image

Image (Kevzara 01p)

KEVZARA (sarilumab) injection, solution, 200 mg/1.14 mL, subcutaneous. The label shows the product name in bold with dosage strength and volume, plus areas for lot number and expiration date. Manufactured by Sanofi-Aventis U.S. LLC. The label is primarily orange and white.*

FDA Label Image

Image (Kevzara 01q)

FDA Label Image

Image (Kevzara 01r)

An instructional illustration showing the KEVZARA (sarilumab) prefilled syringe for subcutaneous injection. The syringe is labeled with KEVZARA 150 mg/1.14 mL and features an orange safety guard. A clock graphic indicates a 30-minute duration, suggesting a step in the administration process.*

FDA Label Image

Image (Kevzara 01s)

Illustration showing recommended subcutaneous injection sites for KEVZARA (sarilumab) on the human body. Highlighted areas include the upper arms, abdomen (excluding the area around the navel), and front thighs. The injection sites are marked in orange.*

FDA Label Image

Image (Kevzara 01t)

An instructional illustration showing a hand removing the protective cap from a syringe prefilled with orange-labeled KEVZARA (sarilumab) injection solution, indicating preparation for subcutaneous administration.*

FDA Label Image

Image (Kevzara 01u)

Illustration showing a hand pinching the skin, likely demonstrating subcutaneous injection technique for a medication such as KEVZARA (sarilumab) injection, solution.*

FDA Label Image

Image (Kevzara 01v)

An instructional illustration showing a hand administering a subcutaneous injection with a syringe at a 45-degree angle into the skin of the opposite arm. The image emphasizes the angle and injection technique for proper delivery of the medication.*

FDA Label Image

Image (Kevzara 01w)

An instructional illustration showing a hand holding a KEVZARA (sarilumab) injection pen for subcutaneous use. The image depicts the step of removing the orange safety cap from the pen before injection.*

FDA Label Image

Image (Kevzara 01x)

An instructional illustration showing a hand holding a KEVZARA (sarilumab) prefilled syringe injection. The syringe is positioned for subcutaneous injection with an arrow indicating the direction to insert the needle into the skin.*

FDA Label Image

Image (Kevzara 01y)

An instructional illustration showing a hand holding a Kevzara (sarilumab) injection syringe with a cap removed, positioned above a disposal container, indicating the syringe is ready to be discarded properly after use.*

FDA Label Image

Image (Kevzara 02)

Illustration of a KEVZARA (sarilumab) 150 mg/1.14 mL single-dose pre-filled pen for subcutaneous injection. The image labels the pen's key components including the label, expiration date, viewing window to see the solution, yellow needle cover, and an orange cap at the bottom.*

FDA Label Image

Image (Kevzara 03)

Label of KEVZARA (sarilumab) injection, 150 mg/1.14 mL, single-dose pre-filled pen for subcutaneous injection. The label includes the NDC number 0024-5920-01, and instructions to refrigerate. The labeler is Sanofi-Aventis U.S. LLC.*

FDA Label Image

Image (Kevzara 04)

Instructional diagram illustrating proper use of the KEVZARA injection device. The top image shows an unused device with a clear viewing window and a green check mark, indicating correct status. The bottom image shows a used device with a yellow fill and a red X mark, indicating it should not be reused.*

FDA Label Image

Image (Kevzara 05)

Illustration showing a KEVZARA 150 mg/1.14 mL prefilled syringe for subcutaneous injection, labeled with dosage strength and usage instructions, accompanied by a clock indicating a 60-minute time period.*

FDA Label Image

Image (Kevzara 06)

An instructional illustration showing possible injection sites for a subcutaneous injection. Orange shaded areas on a human figure indicate the upper arms, abdomen, and upper thighs as recommended injection sites. The figure is labeled 'Injection sites.'*

FDA Label Image

Image (Kevzara 07)

An instructional diagram showing how to remove a protective cap or seal from a syringe or injection device. The image depicts a hand turning and pulling a cap off the orange threaded tip of the syringe before administration.*

FDA Label Image

Image (Kevzara 08)

An instructional illustration showing a hand holding a KEVZARA injection pen at a 90-degree angle to the skin, demonstrating the proper subcutaneous injection technique for the sarilumab solution. The pen label indicates a 150 mg/1.14 mL dosage.*

FDA Label Image

Image (Kevzara 09)

An instructional illustration showing a hand holding a KEVZARA injection pen with a visible dosage label (e.g., 150 mg/1.14 mL). The pen is positioned for subcutaneous injection, with a downward green arrow indicating the injection motion and a label reading 'first click' near the injection site.*

FDA Label Image

Image (Kevzara 10)

An instructional illustration showing the use of a KEVZARA injection device being applied to the skin for subcutaneous administration. A timer icon indicates holding the device in place for up to 15 seconds during injection.*

FDA Label Image

Image (Kevzara 11)

An instructional illustration showing a hand holding a KEVZARA injection device positioned against skin for subcutaneous administration. A green starburst with the text 'second click' indicates an action step during the injection process.*

FDA Label Image

Image (Kevzara 12)

An instructional illustration showing a hand holding a KEVZARA injection pen with a visible dose label of 150 mg/1.14 mL, positioned pointing downwards toward the skin for subcutaneous injection, accompanied by a green upward arrow indicating the injection direction.*

FDA Label Image

Image (Kevzara 13)

An instructional illustration showing a hand holding a KEVZARA (sarilumab) prefilled injection syringe being inserted into a sharps disposal container, demonstrating safe disposal of the used syringe after subcutaneous injection.*

FDA Label Image

Image (Kevzara 14)

KEVZARA 200 mg/1.14 mL pre-filled pen injection for subcutaneous use. The pen displays an orange label with product strength, storage instructions, and NDC 0024-5922-01. It features a yellow needle cover and an orange protective cap, with a window showing the solution inside. Labeler is Sanofi-Aventis U.S. LLC.*

FDA Label Image

Image (Kevzara 15)

Label of KEVZARA (sarilumab) injection showing strength of 200 mg/1.14 mL in a single-dose pre-filled pen. The label indicates that it is for subcutaneous injection only and includes storage instructions to refrigerate. The labeler is Sanofi-Aventis U.S. LLC.*

FDA Label Image

Image (Kevzara 16)

Illustration showing the visual inspection of a Kevzara injection solution. The image indicates a correct unused injection with a clear solution inside the syringe barrel marked by a green check, and an incorrect used injection with a yellow tinted solution marked by a red X. The illustration emphasizes checking the syringe solution before use.*

FDA Label Image

Image (Kevzara 17)

KEVZARA 200 mg/1.14 mL injection, solution in a single-use prefilled syringe for subcutaneous use. The device has an orange cap and a label indicating the dosage strength and manufacturer, Sanofi-Aventis U.S. LLC. The image also includes a graphical clock showing 60 minutes.*

FDA Label Image

Image (Kevzara 18)

An illustration showing recommended injection sites for subcutaneous administration. Highlighted areas in orange indicate injection sites on the upper arms, abdomen, and front thighs of a human figure.*

FDA Label Image

Image (Kevzara 19)

Illustration showing a hand adjusting a spring-loaded injection device with arrows indicating the direction to turn and pull a component, likely demonstrating part of the preparation or use of a subcutaneous injection device.*

FDA Label Image

Image (Kevzara 20)

An instructional illustration showing the proper technique for using a KEVZARA (sarilumab) injection pen. The image depicts a hand holding the pen at a 90-degree angle to the skin, positioned for a subcutaneous injection.*

FDA Label Image

Image (Kevzara 21)

Illustration showing the administration step of KEVZARA (sarilumab) injection, solution, 200 mg/1.14 mL. A hand is pressing down on the auto-injector device against the skin, with a label indicating 'first click' to guide proper use for the subcutaneous injection.*

FDA Label Image

Image (Kevzara 22)

An instructional illustration showing a person using a KEVZARA injection device for subcutaneous administration. The image highlights holding the injector against the skin, with a timer indicating to hold the device in place for up to 15 seconds.*

FDA Label Image

Image (Kevzara 23)

An instructional diagram showing a hand pressing a KEVZARA (sarilumab) injection device vertically against skin. A green burst graphic with the text 'second click' indicates a step in the subcutaneous injection process using the KEVZARA pen injector.*

FDA Label Image

Image (Kevzara 24)

Illustration showing the use of KEVZARA (sarilumab) injection, solution 200 mg/1.14 mL for subcutaneous administration. A hand is holding the autoinjector device vertically above the injection site, with an arrow indicating insertion direction into the skin.*

FDA Label Image

Image (Kevzara 25)

Illustration showing a hand holding a KEVZARA (sarilumab) injection pen above a sharps disposal container. The image demonstrates proper disposal of the used injection device into the container.*

FDA Label Image

Principal Display Panel (150 mg/1.14 mL Syringe Carton)

Packaging label for KEVZARA (sarilumab) injection 150 mg/1.14 mL, a subcutaneous injection solution. The carton contains 2 single-dose pre-filled syringes. Labeler information includes Regeneron and Sanofi Genzyme. The label provides storage instructions, dosage administration guidance, and a highlighted strength panel indicating 150 mg/1.14 mL.*

FDA Label Image

Principal Display Panel (200 mg/1.14 mL Syringe Carton)

Packaging label for KEVZARA (sarilumab) injection, 200 mg/1.14 mL (175.4 mg/mL) solution for subcutaneous injection. The carton contains 2 single-dose pre-filled syringes. Label includes dosage and administration instructions, storage conditions, and manufacturer information—Sanofi-Aventis U.S. LLC in partnership with Regeneron. Prominent orange syringe graphic and dosage strength details are visible.*

FDA Label Image

Principal Display Panel (150 mg/1.14 mL Pen Carton)

Carton packaging label for KEVZARA (sarilumab) injection, 150 mg/1.14 mL (131.6 mg/mL) subcutaneous solution. The label indicates 2 single-dose pre-filled pens per carton. Manufactured and marketed by Sanofi Genzyme and Regeneron. The packaging includes storage instructions, warnings, and a barcode. The syringe image and dosage strength are highlighted on an orange background.*

FDA Label Image

Principal Display Panel (200 mg/1.14 mL Pen Carton)

Packaging label for KEVZARA (sarilumab) injection, 200 mg/1.14 mL (175.4 mg/mL), a subcutaneous injection solution. The carton contains 2 single-dose pre-filled pens. Labeler information includes Sanofi Genzyme and Regeneron. The label provides storage instructions, dosage form, and a barcode, emphasizing the 200 mg/1.14 mL strength prominently in orange.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.